GS 5829

Drug Profile

GS 5829

Alternative Names: GS5829

Latest Information Update: 28 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Prostate cancer
  • Phase I Lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 01 Jan 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02983604)
  • 03 Dec 2016 Pharmacokinetics and Pharmacodynamics data from preclinical trial in Diffuse large B cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (3218946; 3224662)
  • 03 Dec 2016 Pharmacodynamics data from preclinical trial in Diffuse large B cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top